Be-cause Health & QUAMED literature updates
Ref. Yaneth Gil-Rojas et al. Cost-effectiveness of Carbetocin versus Oxytocin for Prevention of Postpartum Hemorrhage Resulting from Uterine Atony in Women at high-risk for bleeding in Colombia. Rev Bras Ginecol Obstet 2018; 40(05): 242-250 DOI: 10.1055/s-0038-1655747
In the 21st edition of the WHO Model List of Essential Medicines issued in June 2019, heat stable carbetocin was added to the core list of medicines for reproductive health. Despite the potential great importance of this product, little is known on its availability and pricing in different contexts. Therefore, some may be interested in the attached study from Colombia, published in 2018. The economic model developed for cesarean section shows that carbetocin had greater effectiveness and lower costs, making it a dominant alternative for the prevention of PPH in high-risk patients; however, the model developed for vaginal delivery shows that carbetocin cost was higher than the acceptable threshold, for Colombia. Should we have similar insights from other countries, it could be interesting to share them in our network.
I also take this opportunity to share the new issue (16th April) of the Medical Product Quality Report – COVID-19 vaccine issues from our IDDO Friends. Sadly, between 12th March 2020 and 31st March 2021, 94 reports of diverted or SF COVID-19 vaccines from 32 countries appeared in the lay press; there were also fifteen public domain reports of diverted COVID-19 vaccines. The authors note ‘’inequitable access is highly likely to fuel an increase in such incidents, negating the global good on health and economy of these remarkable vaccines. We urgently need joined-up interventions to reduce the risk of SF COVID-19 vaccines on global public health, through significant enhancements in global capacity for their prevention, detection and response’’.
Have a nice reading,